14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $11.01 $15.18 Thursday, 25th Apr 2024 IOVA stock ended at $11.54. This is 1.45% less than the trading day before Wednesday, 24th Apr 2024. During the day the stock fluctuated 4.39% from a day low at $11.16 to a day high of $11.65.
90 days $7.34 $18.33
52 weeks $3.21 $18.33

Historical Iovance Biotherapeutics, Inc. prices

Date Open High Low Close Volume
Apr 25, 2024 $11.50 $11.65 $11.16 $11.54 3 302 150
Apr 24, 2024 $11.92 $12.13 $11.68 $11.71 2 585 435
Apr 23, 2024 $11.42 $11.97 $11.41 $11.86 3 810 802
Apr 22, 2024 $11.54 $11.64 $11.07 $11.32 2 360 449
Apr 19, 2024 $11.60 $11.69 $11.01 $11.31 5 181 883
Apr 18, 2024 $11.68 $11.91 $11.48 $11.72 3 565 908
Apr 17, 2024 $11.96 $12.12 $11.65 $11.80 3 050 966
Apr 16, 2024 $11.79 $12.14 $11.53 $11.92 5 394 829
Apr 15, 2024 $12.35 $12.53 $11.66 $11.89 6 375 935
Apr 12, 2024 $13.01 $13.13 $12.17 $12.36 4 426 929
Apr 11, 2024 $12.64 $13.22 $12.49 $13.19 3 645 982
Apr 10, 2024 $12.66 $12.73 $12.11 $12.58 5 605 625
Apr 09, 2024 $13.07 $13.30 $12.91 $13.22 4 224 168
Apr 08, 2024 $13.59 $13.59 $12.89 $13.07 4 604 823
Apr 05, 2024 $13.48 $13.89 $13.20 $13.53 3 376 135
Apr 04, 2024 $14.08 $14.21 $13.40 $13.60 4 028 815
Apr 03, 2024 $13.59 $14.20 $13.27 $14.01 4 504 478
Apr 02, 2024 $13.85 $14.16 $13.56 $13.77 5 449 975
Apr 01, 2024 $14.71 $14.75 $13.99 $14.19 4 004 978
Mar 28, 2024 $14.12 $15.18 $14.10 $14.82 6 055 141
Mar 27, 2024 $14.20 $14.32 $13.75 $14.10 3 789 127
Mar 26, 2024 $14.81 $15.04 $13.95 $14.05 5 005 812
Mar 25, 2024 $15.00 $15.50 $14.44 $14.53 4 523 627
Mar 22, 2024 $15.23 $15.44 $14.86 $15.02 3 643 184
Mar 21, 2024 $15.04 $15.90 $15.02 $15.36 7 134 522
Click to get the best stock tips daily for free!

About Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics. Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or pers... IOVA Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT